Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

Por Bradshaw-Pierce, Erica L., Pitts, Todd M., Kulikowski, Gillian, Selby, Heather, Merz, Andrea L., Gustafson, Daniel L., Serkova, Natalie J., Eckhardt, S. Gail, Weekes, Colin D.
Publicado em 2013

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

Por Pitts, Todd M., Tan, Aik Choon, Kulikowski, Gillian N., Tentler, John J., Brown, Amy M., Flanigan, Sara A., Leong, Stephen, Coldren, Christopher D., Hirsch, Fred R., Varella-Garcia, Marileila, Korch, Christopher, Eckhardt, S. Gail
Publicado em 2010

Overcoming IGF1R/IR Resistance Through Inhibition of MEK Signaling in Colorectal Cancer Models

Por Flanigan, Sara A., Pitts, Todd M., Newton, Timothy P., Kulikowski, Gillian N., Tan, Aik Choon, McManus, Martine C., Spreafico, Anna, Kachaeva, Maria I., Selby, Heather M., Tentler, John J., Eckhardt, S. Gail, Leong, Stephen
Publicado em 2013

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

Por Morelli, M. Pia, Tentler, John J., Kulikowski, Gillian N., Tan, Aik-Choon, Bradshaw-Pierce, Erica L., Pitts, Todd M., Brown, Amy M., Nallapareddy, Sujatha, Arcaroli, John J., Serkova, Natalie J., Hidalgo, Manuel, Ciardiello, Fortunato, Eckhardt, S. Gail
Publicado em 2011

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

Por Tentler, John J., Nallapareddy, Sujatha, Tan, Aik Choon, Spreafico, Anna, Pitts, Todd M., Morelli, M. Pia, Selby, Heather M., Kachaeva, Maria I., Flanigan, Sara A., Kulikowski, Gillian N., Leong, Stephen, Arcarol, John J., Messersmith, Wells A., Eckhardt, S. Gail
Publicado em 2010

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors

Por Diamond, Jennifer R., Bastos, Bruno R., Hansen, Ryan J., Gustafson, Daniel L., Eckhardt, S. Gail, Kwak, Eunice L., Pandya, Shuchi S., Fletcher, Graham C., Pitts, Todd M., Kulikowski, Gillian N., Morrow, Mark, Arnott, Jamie, Bray, Mark R., Sidor, Carolyn, Messersmith, Wells, Shapiro, Geoffrey I.
Publicado em 2010

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

Por Pitts, Todd M., Kulikowski, Gillian N., Tan, Aik-Choon, Murray, Brion W., Arcaroli, John J., Tentler, John J., Spreafico, Anna, Selby, Heather M., Kachaeva, Maria I., McPhillips, Kelly L., Britt, Blair C., Bradshaw-Pierce, Erica L., Messersmith, Wells A., Varella-Garcia, Marileila, Eckhardt, S. Gail
Publicado em 2013